Trazodone has very low abuse potential compared to the sleep medications it often replaces, and it is not classified as a controlled substance in the United States. In head-to-head laboratory studies, people given trazodone reported significantly less willingness to take it again than those given benzodiazepines or similar sedatives, which is one of the standard measures researchers use to gauge whether a drug is likely to be misused. That said, “very low” is not zero: diversion of trazodone has been rising steadily for over a decade, and some people do take it outside of a prescription, usually for its sedating effects rather than any kind of high.
Why Trazodone Is Considered Low Risk for Abuse
Most drugs people abuse share a common thread: they either flood the brain with dopamine, amplify the calming effects of GABA, or both. Trazodone does neither. Its main action is blocking certain serotonin receptors, especially one called 5-HT2A, and it also blocks a receptor involved in the body’s adrenaline response. Those two actions together produce sedation, which is why doctors prescribe it for sleep, but the sedation it creates feels more like drowsiness than the pleasurable relaxation that benzodiazepines or opioids produce. Trazodone has very low affinity for dopamine, GABA/benzodiazepine, or acetylcholine muscarinic receptors, all of which are implicated in the rewarding effects of commonly abused drugs.1Wiley Online Library (Clinical and Translational Science). Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
In practical terms, this means trazodone does not produce euphoria, does not create the kind of physical dependence that leads to dangerous withdrawal syndromes, and does not escalate in the way that addictive substances tend to. People who take it for sleep generally stay at the same dose rather than needing more over time. That pharmacological profile is the main reason the Drug Enforcement Administration has never placed trazodone on any schedule of controlled substances, even as prescriptions for it have grown enormously.
What the Lab Studies Actually Show
The most direct evidence about trazodone’s abuse potential comes from a controlled study that compared it to triazolam, a short-acting benzodiazepine, and zolpidem (the active ingredient in Ambien). Researchers gave all three drugs to participants and measured subjective responses, including how much participants liked the drug, how “high” they felt, and whether they would be willing to take it again. Trazodone scored lower than triazolam on every measure thought to predict abuse. Zolpidem, by contrast, produced effects comparable to the benzodiazepine on those same measures.2PubMed. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans
The researchers concluded that trazodone could be a viable alternative to benzodiazepine-type sleep medications for people with histories of alcohol or drug problems. That finding has shaped clinical practice for decades: trazodone is one of the go-to sleep aids prescribed to people recovering from substance use disorders precisely because it helps with insomnia without introducing a new addiction risk.
How Widely Trazodone Is Prescribed
To understand why trazodone comes up in conversations about misuse at all, it helps to know just how common the drug has become. Trazodone was originally approved as an antidepressant, but its off-label use for insomnia has long since overtaken that original purpose.3PubMed Central. Trazodone for Insomnia: A Systematic Review In 2019, roughly 24 million trazodone prescriptions were filled in the United States, and at least 85 percent of them were for off-label uses, primarily insomnia.4Health Affairs Scholar. Off-label policy through the lens of trazodone usage and spending in the United States That volume matters: when tens of millions of prescriptions circulate annually, even a small percentage of misuse translates into meaningful numbers of people obtaining the drug outside normal channels.
The sheer scale of prescribing also means trazodone is easy to come by. It is inexpensive (pharmacies are typically reimbursed around $10 per prescription), it is unscheduled, and most clinicians view it as relatively safe to prescribe. All of those factors make it more accessible than controlled sleep medications, which require special prescribing practices and monitoring.
Diversion Is Rising, Even If Rates Are Still Low
Diversion refers to prescription drugs ending up in the hands of someone other than the person they were prescribed to, whether through theft, sharing, or sale. A study tracking nonscheduled psychoactive medications between 2002 and 2017 found that trazodone diversion rates increased more than fivefold over that period. The same pattern held for quetiapine and cyclobenzaprine, two other nonscheduled medications that produce sedation. By 2017, the annual diversion rate for these drugs was still far below that of opioid painkillers, but unlike opioid diversion, which had started declining by that point, the rate for trazodone and the others kept climbing.5PubMed. The diversion of nonscheduled psychoactive prescription medications in the United States, 2002 to 2017
Why would anyone divert a drug that does not produce euphoria? A few reasons. Some people simply want help sleeping and cannot or do not want to see a doctor for a prescription. Others, particularly people in correctional or inpatient settings where more desirable drugs are unavailable, will use whatever sedating medication they can get. And in some cases, people combine trazodone with other substances to amplify effects, which introduces its own set of risks.
Trazodone in Substance Use Disorder Treatment
Insomnia is extremely common in people recovering from alcohol or drug dependence. Poor sleep is both a symptom of withdrawal and a persistent complaint that can last months after someone stops using. The challenge for clinicians is finding a sleep aid that actually works without creating a new dependency. Benzodiazepines and the related “Z-drugs” like zolpidem are generally discouraged in this population because of their own addiction potential and the risk of fatal overdose when mixed with other depressants.
That leaves a relatively short list of options, and trazodone is among the most commonly used. Clinical practice guidelines acknowledge that the off-label use of trazodone, along with medications like quetiapine, mirtazapine, and gabapentin, is widespread for treating insomnia in people with substance use disorders, and that it can be justified particularly when patients also have other psychiatric conditions like depression or anxiety.6Journal of Addiction & Addictive Disorders. Approach to Treat Insomnia in Substance Use Disorder Population The preference is always to try behavioral approaches to insomnia first, but when medication is necessary, trazodone’s low abuse profile makes it a safer bet than the alternatives.
This is one of those situations where context matters enormously. The same property that makes trazodone attractive in addiction treatment, its lack of euphoric effects, is also why its misuse tends to look different from that of more rewarding drugs. People misusing trazodone are usually chasing sedation and sleep, not a high. That distinction shapes both the clinical risk and how seriously the misuse should be taken.
What Happens in Overdose
One reason trazodone’s rising diversion deserves attention, even though the drug is not particularly rewarding, is that taking too much of it can cause serious medical problems. The primary danger in trazodone overdose is severe hypotension, meaning blood pressure drops to dangerously low levels. A published case report described a patient who intentionally ingested an estimated 2,500 mg, far beyond any therapeutic dose, and developed persistent hypotension requiring intensive care, aggressive fluid resuscitation, and drugs to raise blood pressure.7PubMed Central. Management of Trazodone Overdose with Severe Hypotension
Other complications can include excessive sedation, dizziness, irregular heart rhythms, and in rare cases seizures. Trazodone is also notorious for causing priapism, a prolonged and painful erection that constitutes a medical emergency. While trazodone is far less lethal in overdose than tricyclic antidepressants or benzodiazepines combined with other sedatives, it is not harmless. People who take large amounts, especially in combination with alcohol or other central nervous system depressants, can end up critically ill.
The overdose profile reinforces a point worth making explicitly: “low abuse potential” and “safe to misuse” are not the same thing. A drug can be unappealing as a substance of abuse while still being dangerous when taken incorrectly.
How Trazodone Compares to Other Sleep Medications
It is useful to put trazodone’s abuse potential in context by comparing it to the other medications commonly prescribed for sleep. Benzodiazepines like triazolam and temazepam are Schedule IV controlled substances, reflecting their well-established potential for dependence, tolerance, and withdrawal. The Z-drugs, including zolpidem and eszopiclone, are also Schedule IV. Even suvorexant, a newer type of sleep aid that works through a different mechanism (blocking orexin receptors), has been placed in Schedule IV because of some observed abuse signals in clinical trials.
Trazodone sits outside all of that. It is the most commonly used pharmacological treatment for insomnia in the United States despite having no FDA approval for that indication, and it remains unscheduled. The lab data support this distinction: when directly compared to a benzodiazepine in the same study, trazodone consistently scored lower on every measure of abuse liability.2PubMed. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans That does not mean it is the most effective sleep medication available, and the evidence for its efficacy in insomnia is actually somewhat limited. But when the primary concern is avoiding a drug with addiction risk, trazodone fills a niche that few other options can.
The Role of Its Metabolite, mCPP
When your body breaks down trazodone, the primary enzyme involved is CYP3A4, and one of the resulting metabolites is a compound called mCPP (meta-chlorophenylpiperazine).8Frontiers in Pharmacology. Characterization of trazodone metabolic pathways and species-specific profiles This metabolite is pharmacologically active and has a complicated history. mCPP has been sold as a recreational drug in its own right in some countries, typically in tablet form and sometimes misrepresented as ecstasy. It acts on serotonin receptors and can produce anxiety, restlessness, and mild psychoactive effects.
In the context of trazodone therapy, the amount of mCPP produced at normal doses is generally small enough that it does not cause noticeable problems for most people. But the metabolite’s existence does mean that trazodone’s pharmacological footprint is not as simple as it first appears. People who metabolize the drug more slowly, including those taking medications that inhibit CYP3A4 (certain antifungals, some antibiotics, grapefruit juice in large quantities), may accumulate more mCPP. Human liver cells actually process trazodone more slowly than those of other species, which means the drug tends to stick around longer in the body and maintain relatively stable blood levels.8Frontiers in Pharmacology. Characterization of trazodone metabolic pathways and species-specific profiles For most patients this is clinically irrelevant, but it adds a wrinkle for anyone taking trazodone alongside drugs that compete for the same metabolic pathway.
Why Dose Matters More Than People Realize
Trazodone’s effects shift substantially depending on how much you take. At low doses, typically 25 to 50 mg, the dominant action is blocking serotonin 5-HT2A receptors and alpha-1 adrenergic receptors. The result is drowsiness without much else, which is why low-dose trazodone is the version most people encounter as a sleep aid. At higher antidepressant doses, starting around 150 mg and going up to 300 mg per day, the drug begins to block the serotonin transporter, which is the mechanism responsible for its antidepressant effect.1Wiley Online Library (Clinical and Translational Science). Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
This dose-dependent shift matters for the abuse question because it means the trazodone most people have access to, the low-dose sleep version, is essentially a sedative with no euphoric or mood-elevating component. Taking more of it does not produce a “better” version of the sedation; it just adds side effects like next-day grogginess, dizziness, and nausea. The experience of escalating the dose is unpleasant, which is the opposite of what happens with drugs that have genuine reinforcing properties. This built-in ceiling is a significant part of why trazodone abuse remains uncommon even as the drug has become ubiquitous.
When You Should Still Be Cautious
Even with its favorable abuse profile, trazodone is not something to take casually. Stopping it abruptly after regular use can produce a discontinuation syndrome: insomnia rebound, irritability, and sometimes anxiety. This is not the same as withdrawal from an addictive substance, but it is uncomfortable enough that most doctors recommend tapering off rather than stopping cold. If you have been taking trazodone nightly for months and want to stop, talk to whoever prescribed it about a gradual reduction plan.
Trazodone also interacts with a wide range of medications. Combining it with other serotonergic drugs (including common antidepressants like SSRIs and SNRIs) raises the risk of serotonin syndrome, a potentially serious condition involving agitation, rapid heart rate, and high body temperature. Mixing it with alcohol or other sedatives amplifies the sedation and blood-pressure-lowering effects, which is where some of the more dangerous misuse scenarios arise. People who combine trazodone with benzodiazepines or opioids, whether recreationally or just because they have multiple prescriptions, face a meaningfully higher risk of respiratory depression and cardiovascular complications than they would with any of those drugs alone.
For the large majority of people who take trazodone as prescribed, the drug is well-tolerated and effective for what it is asked to do. The abuse question is real but should be kept in proportion: trazodone is one of the least-abused psychoactive medications on the market, and its rising diversion, while worth monitoring, is a small-scale phenomenon compared to the challenges posed by opioids, benzodiazepines, or stimulants.